{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:27:46Z","timestamp":1790033266967,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02512-w","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:02:34Z","timestamp":1727431354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of short-term Peg-IFN \u03b1-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"4","key":"2512_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","volume":"20","author":"SG Lim","year":"2023","unstructured":"Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Reviews Gastroenterol Hepatol. 2023;20(4):238\u201353.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"2512_CR2","unstructured":"World Health Organization. Hepatitis B Fact Sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed 9 April 2024."},{"key":"2512_CR3","first-page":"m2200","volume":"370","author":"Y Shi","year":"2020","unstructured":"Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ (Clinical Res ed). 2020;370:m2200.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"3","key":"2512_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","volume":"75","author":"MG Martinez","year":"2021","unstructured":"Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75(3):706\u201317.","journal-title":"J Hepatol"},{"issue":"11","key":"2512_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discovery. 2019;18(11):827\u201344.","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"2512_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.cmi.2021.06.024","volume":"28","author":"Z Dai","year":"2022","unstructured":"Dai Z, Wong IOL, Xie C, Xu W, Xiang Y, Peng L, et al. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China. Clin Microbiol Infect. 2022;28(2):300..e1-.e8.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2512_CR7","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","volume":"19","author":"HSJ Choi","year":"2021","unstructured":"Choi HSJ, van Campenhout MJH, van Vuuren AJ, Krassenburg LAP, Sonneveld MJ, de Knegt RJ, et al. Ultra-long-term follow-up of Interferon Alfa treatment for HBeAg-Positive chronic Hepatitis B Virus infection. Clin Gastroenterol Hepatol. 2021;19(9):1933\u2013e401.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2512_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/jvh.13722","volume":"29","author":"JH Chu","year":"2022","unstructured":"Chu JH, Huang Y, Xie DY, Deng H, Wei J, Guan YJ, et al. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients. J Viral Hepatitis. 2022;29(9):765\u201376.","journal-title":"J Viral Hepatitis"},{"key":"2512_CR9","doi-asserted-by":"publisher","first-page":"894410","DOI":"10.3389\/fimmu.2022.894410","volume":"13","author":"WX Wang","year":"2022","unstructured":"Wang WX, Jia R, Gao YY, Liu JY, Luan JQ, Qiao F, et al. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-\u03b1 in NA-suppressed chronic hepatitis B patients. Front Immunol. 2022;13:894410.","journal-title":"Front Immunol"},{"key":"2512_CR10","doi-asserted-by":"publisher","first-page":"1121778","DOI":"10.3389\/fimmu.2023.1121778","volume":"14","author":"WX Wang","year":"2023","unstructured":"Wang WX, Jia R, Jin XY, Li X, Zhou SN, Zhang XN, et al. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-\u03b1 in NAs-suppressed chronic hepatitis B patients. Front Immunol. 2023;14:1121778.","journal-title":"Front Immunol"},{"issue":"10","key":"2512_CR11","first-page":"756","volume":"26","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, et al. [HBsAg loss with pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study]. Chin J Hepatol. 2018;26(10):756\u201364.","journal-title":"Chin J Hepatol"},{"issue":"3","key":"2512_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41575-020-00398-x","volume":"18","author":"AL McNaughton","year":"2021","unstructured":"McNaughton AL, Lemoine M, van Rensburg C, Matthews PC. Extending treatment eligibility for chronic hepatitis B virus infection. Nat Reviews Gastroenterol Hepatol. 2021;18(3):146\u20137.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"4","key":"2512_CR13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","volume":"78","author":"L Wang","year":"2023","unstructured":"Wang L, Zhu Q, Zhang JD, Zhang Y, Ni X, Xiang K, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2023;78(4):742\u201353.","journal-title":"J Hepatol"},{"issue":"1","key":"2512_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/apt.16659","volume":"55","author":"A Vittal","year":"2022","unstructured":"Vittal A, Sharma D, Hu A, Majeed NA, Terry N, Auh S, et al. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022;55(1):8\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2512_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ng.2295","volume":"44","author":"WK Sung","year":"2012","unstructured":"Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765\u20139.","journal-title":"Nat Genet"},{"key":"2512_CR16","doi-asserted-by":"publisher","first-page":"779347","DOI":"10.3389\/fimmu.2021.779347","volume":"12","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, et al. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: a Meta-analysis. Front Immunol. 2021;12:779347.","journal-title":"Front Immunol"},{"issue":"9","key":"2512_CR17","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1111\/liv.14897","volume":"41","author":"F Wu","year":"2021","unstructured":"Wu F, Lu R, Liu Y, Wang Y, Tian Y, Li Y, et al. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver Int. 2021;41(9):2032\u201345.","journal-title":"Liver Int"},{"issue":"6","key":"2512_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249\u201362.","journal-title":"J Hepatol"},{"issue":"13","key":"2512_CR19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen\u2009\u2264\u20091500 IU\/mL: an observational study. World J Gastroenterol. 2020;26(13):1525\u201339.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2512_CR20","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s40121-021-00497-5","volume":"10","author":"J Chen","year":"2021","unstructured":"Chen J, Qi M, Fan XG, Hu XW, Liao CJ, Long LY, et al. Efficacy of Peginterferon alfa-2b in Nucleoside Analogue experienced patients with negative HBeAg and low HBsAg: a non-randomized clinical trial. Infect Dis Therapy. 2021;10(4):2259\u201370.","journal-title":"Infect Dis Therapy"},{"key":"2512_CR21","doi-asserted-by":"publisher","first-page":"1104329","DOI":"10.3389\/fimmu.2022.1104329","volume":"13","author":"P Wang","year":"2022","unstructured":"Wang P, Mo Z, Zhang Y, Guo C, Chikede TK, Chen D, et al. Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon. Front Immunol. 2022;13:1104329.","journal-title":"Front Immunol"},{"key":"2512_CR22","doi-asserted-by":"publisher","first-page":"1116160","DOI":"10.3389\/fimmu.2022.1116160","volume":"13","author":"Y Lin","year":"2022","unstructured":"Lin Y, Shen G, Xie S, Bi X, Lu H, Yang L, et al. Dynamic changes of the proportion of HLA-DR and CD38 coexpression subsets on T lymphocytes during IFN-based chronic hepatitis B treatment. Front Immunol. 2022;13:1116160.","journal-title":"Front Immunol"},{"issue":"3","key":"2512_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bpg.2017.05.003","volume":"31","author":"LL Boeijen","year":"2017","unstructured":"Boeijen LL, Hoogeveen RC, Boonstra A, Lauer GM. Hepatitis B virus infection and the immune response: the big questions. Best Pract Res Clin Gastroenterol. 2017;31(3):265\u201372.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"2512_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jiv397","volume":"213","author":"L Jansen","year":"2016","unstructured":"Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL, Hepatitis B, Virus Pregenomic. RNA is Present in Virions in plasma and is Associated with a response to Pegylated Interferon Alfa-2a and Nucleos(t)ide analogues. J Infect Dis. 2016;213(2):224\u201332.","journal-title":"J Infect Dis"},{"issue":"1","key":"2512_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-021-00776-0","volume":"6","author":"D Wang","year":"2021","unstructured":"Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, et al. Restoration of HBV-specific CD8\u2009+\u2009T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-\u03b1 therapy. Signal Transduct Target Therapy. 2021;6(1):376.","journal-title":"Signal Transduct Target Therapy"},{"key":"2512_CR26","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijid.2020.05.041","volume":"96","author":"X Bao","year":"2020","unstructured":"Bao X, Guo J, Xiong F, Qu Y, Gao Y, Gu N, et al. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs. Int J Infect Dis. 2020;96:562\u20136.","journal-title":"Int J Infect Dis"},{"issue":"7","key":"2512_CR27","doi-asserted-by":"publisher","first-page":"e0270716","DOI":"10.1371\/journal.pone.0270716","volume":"17","author":"HY Woo","year":"2022","unstructured":"Woo HY, Heo J, Tak WY, Lee HJ, Chung WJ, Park JG, et al. Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized trial. PLoS ONE. 2022;17(7):e0270716.","journal-title":"PLoS ONE"},{"issue":"3","key":"2512_CR28","first-page":"202","volume":"2","author":"N Gupta","year":"2014","unstructured":"Gupta N, Goyal M, Wu CH, Wu GY. The molecular and structural basis of HBV-resistance to Nucleos(t)ide analogs. J Clin Translational Hepatol. 2014;2(3):202\u201311.","journal-title":"J Clin Translational Hepatol"},{"issue":"4","key":"2512_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800\u20136.","journal-title":"J Hepatol"},{"issue":"2","key":"2512_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","volume":"224","author":"J Li","year":"2021","unstructured":"Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH, et al. Association between fatty liver and cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. J Infect Dis. 2021;224(2):294\u2013302.","journal-title":"J Infect Dis"},{"issue":"9","key":"2512_CR31","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/apt.16595","volume":"54","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1100\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2512_CR32","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","volume":"26","author":"MV Machado","year":"2011","unstructured":"Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"2512_CR33","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","volume":"12","author":"D Hu","year":"2018","unstructured":"Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hep Intl. 2018;12(5):438\u201346.","journal-title":"Hep Intl"},{"issue":"4","key":"2512_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/17474124.2021.1866985","volume":"15","author":"ML Yeh","year":"2021","unstructured":"Yeh ML, Huang JF, Yu ML, Chuang WL. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. Expert Rev Gastroenterol Hepatol. 2021;15(4):427\u201335.","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02512-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02512-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02512-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:16:52Z","timestamp":1727432212000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02512-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2512"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02512-w","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study obtained ethical approval from the Ethics Board at The Second Affiliated Hospital of Harbin Medical University (KY2024-049).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the final version of the manuscript. Consent for the publication of data, images, or information was obtained from all participants (or their legal guardians) where applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}